(rac)-4-(4'-Ethoxy-biphenyl-4-yl)-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-ethyl]-4-oxo-butyric acid | 289485-14-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (rac)-4-(4'-Ethoxy-biphenyl-4-yl)-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-ethyl]-4-oxo-butyric acid
• 英文别名: 4-[4-(4-Ethoxyphenyl)phenyl]-4-oxo-2-[2-(4-oxo-1,2,3-benzotriazin-3-yl)ethyl]butanoic acid
• CAS: 289485-14-9
• 化学式: C₂₇H₂₅N₃O₅
• 分子量: 471.513
• InChiKey: SKIBYIMWGNHOAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
  申请人：Bayer Aktiengesellschaft

  公开号：EP1031349A1

  公开（公告）日：2000-08-30

  Use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the Treatment of Cerebral Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula         (T)xA-B-D-E-CO2H wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0, 1, or 2; the group D represents 〉C=O , or the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.

  使用替代的4-联苯丁酸和5-联苯戊酸衍生物治疗脑部疾病，包含它们的药物组合物，以及使用它们的方法。 该发明的化合物具有一般化学式         (T)xA-B-D-E-CO2H 其中A是芳基或杂环芳基；B是芳基或杂环芳基或键；每个T是取代基；x为0、1或2；D代表〉C=O，或 E代表一个带有一个到三个取代基的两个或三个碳链，这些取代基是独立的或参与环形成，可能的结构在文本和权利要求中显示；E上的每个取代基都是独立的取代基；并包括其药用盐。
• USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBRAL DISEASES
  申请人：Bayer Aktiengesellschaft

  公开号：EP1087761A2

  公开（公告）日：2001-04-04
• USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：Bayer Aktiengesellschaft

  公开号：EP1217994A2

  公开（公告）日：2002-07-03
• [EN] USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBRAL DISEASES<br/>[FR] UTILISATION DE DERIVES SUBSTITUES D'ACIDES 4-BIARYLBUTYRIQUE ET 5-BIARYLPENTANOIQUE POUR LE TRAITEMENT DES MALADIES CEREBRALES
  申请人：BAYER AG

  公开号：WO2000050017A2

  公开（公告）日：2000-08-31

  Use of subtsituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the Treatment of Cerebral Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (I): (T)xA-B-D-E-CO2H, wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0,1, or 2; the group D represents (a), or (b), the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and includes pharmaceutically acceptable salts thereof.
• [EN] USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS<br/>[FR] UTILISATION DE DERIVES D'ACIDE 4-BIARYLBUTYRIQUE ET D'ACIDE 5-BIARYLPENTANOIQUE SUBSTITUES POUR LE TRAITEMENT DE LA SCLEROSE EN PLAQUES
  申请人：BAYER AG

  公开号：WO2001022951A2

  公开（公告）日：2001-04-05

  Use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the Prevention and Treatment of Multiple Sclerosis, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (T)xA-B-D-E-CO2H wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0, 1, or 2; the group D represents Formulae (a) or (b), the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.